Lablabo creates pack for HRT treatment

Published: 24-Jan-2011
Drug Delivery Pharmaceutical

Uses an airless metering dispenser with EasyFoil aluminium pouch

Lablabo creates pack for HRT treatment
Lablabo of France has developed a high-performance airless pack for Azur Pharma’s Elestrin hormonal replacement therapy, which has been launched in the US following approval by the US Food and Drug Administration.

Lablabo’s pack consists of a Sillage airless metering dispenser with an EasyFoil aluminium pouch.

Made of an aluminium and polyethylen multilayer foil, this new pouch is said to ensure maximum protection of the product inside against oxygen and UV rays. Its cylindrical shape guarantees high restitution rates (up to 98% of the product delivered) and easy filling with basic equipment, the firm says.

The metering pump delivers a constant and precise dose of 0.92ml.

The Elestrin sales pack used by the Irish pharmaceutical firm includes two 38ml Sillage airless metering dispensers for a two-month treatment.

Lablabo, based in Annemasse, says it has Drug Master Files (DMFs) registered with the FDA for all of it products and received ISO 15378 certification last December.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Taking biologic therapies out of the clinic

Taking biologic therapies out of the clinic

Read more
How larger autoinjectors are changing drug delivery device testing

Trending Articles

  1. Pharma’s silent sustainability risk and the supply chain fix Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
  2. UK liquid manufacturing: why British production matters for healthcare and the economy How specialist liquid manufacturing in Newcastle supports UK healthcare supply chains, skilled employment and pharmaceutical and nutraceutical production
  3. From speed to strategy: how UK life sciences should respond to China’s rise A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?
  4. ESTEVE CDMO invests $80m in new China API manufacturing site The Shaoxing facility will provide 250 m³ of reaction volume, with potential capacity exceeding 400 m³, as the CDMO expands its global small-molecule API manufacturing network
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    UK Budget 2026: what it means for pharma manufacturing VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Taking biologic therapies out of the clinic

Taking biologic therapies out of the clinic

How larger autoinjectors are changing drug delivery device testing
Ingredients
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny

The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics

The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
Bavarian Nordic secures four-year UK vaccine supply contract

Bavarian Nordic secures four-year UK vaccine supply contract

The agreement with the UK Health Security Agency will see the Danish vaccine manufacturer supply its MVA-BN mpox and smallpox vaccine, supporting the UK's long-term infectious disease preparedness
Pharmaceutical
Pharma’s silent sustainability risk and the supply chain fix

Pharma’s silent sustainability risk and the supply chain fix

Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
UK Budget 2026: what it means for pharma manufacturing

UK Budget 2026: what it means for pharma manufacturing

VAT relief on free medicines, £1bn in new investment and revised capital allowances give pharma manufacturers progress — but gaps remain
Manufacturing
How to remove impurities without wasting solvent using ANFD technology

How to remove impurities without wasting solvent using ANFD technology

Discover how Agitated Nutsche Filter Dryers (ANFDs) optimise API cake washing. Combine re-slurry agitation with in-process monitoring to hit target purity while reducing overall solvent waste
Subscribe now